Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration

• Published in: Gan to kagaku ryoho Vol. 17; no. 12; p. 2333
• Main Authors: Yamada, K, Hase, S, Yoshimura, A, Haruyama, K, Katsura, Y, Sameshima, T, Niwa, K, Ishizawa, T, Shimazu, H
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.12.1990
• Subjects: Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - enzymology; Colorectal Neoplasms - metabolism; Combined Modality Therapy; Delayed-Action Preparations; Fluorouracil - blood; Fluorouracil - pharmacokinetics; Humans; Portal Vein; Tegafur - administration & dosage; Tegafur - pharmacokinetics; Tegafur - therapeutic use; Thymidine Phosphorylase - metabolism; Tissue Distribution
• ISSN: 0385-0684

5-fluorouracil (5-FU) concentrations in peripheral blood, portal blood, normal and cancer tissues were evaluated in 26 patients with colorectal cancer after SF-SP administration (800 mg/day for 10 days). Thymidine phosphorylase activity in cancer tissues was also evaluated. 5-FU concentration in cancer tissues was significantly higher than that in other three specimens, and much higher than 0.05 microgram/g which was reported to be the minimum effective concentration. 5-FU concentration in portal blood was lower than MEC (0.05 microgram/ml). As for the relationship with the pathological features of cancer, the protruding lesions showed a higher 5-FU concentration than the ulcerative ones, and the lesions invaded only to submucosa or proper muscle showed a higher concentration than others. 5-FU concentration ratio in cancer tissues per in peripheral blood (T/B ratio) was related to thymidine phosphorylase activity. The higher was the thymidine phosphorylase activity, the greater T/B ratio. The results suggest that the tumor with higher thymidine phosphorylase activity might have a more pronounced anticancer efficacy of 5-FU.